A Phase 2 interventional study of Sotatercept and SOC in Pulmonary Arterial Hypertension, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 15th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 2nd registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan
Ages 1–17
Kazuya Hosokawa · Sites in Japan
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18–70
Merck Sharp & Dohme LLC · Sites in United States, Australia, Colombia and 9 more countries
Ages 1–17
By country, each count listing its studies:
sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2019.
This study's enrollment of 21 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 44 across the 18 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, one of the names counted as Merck & Co., Inc. Under that name alone:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc: 3 open now, 5 under way, 1 of them phase 3. Of 12 finished, 11 (92%) have results posted.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 15th largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 2, and was the 5th registered.
Merck & Co., Inc’s Pulmonary Arterial Hypertension studies by the year they started, since 2013.
1 of the studies testing sotatercept in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356778Kazuya HosokawaA Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, from their registry updates:
Among Merck & Co., Inc’s 17 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effect of sotatercept (ACE-011) in adults with pulmonary arterial hypertension (PAH). Each eligible participant will receive standard of care (SOC) plus sotatercept (ACE-011) for a 24-week treatment period, followed by an 18-month extension period, and an 8-week follow-up period.
This is a Phase 2a, single-arm, open-label, multicenter exploratory study to determine the effects of sotatercept plus SOC in adults with WHO functional class III PAH.
All eligible participants will receive SOC plus sotatercept at a starting dose level of 0.3 mg/kg by subcutaneous (SC) injection for Cycle 1 and escalating to 0.7 mg/kg at Cycle 2 for the remainder of the treatment period. Participants will be required to attend clinic visits once every three weeks for the 24-week treatment period and once every three weeks for the 18-month extension period to perform one or more protocol specified evaluations. Evaluations include hemodynamic measures collected during right heart catheterization (RHC) with invasive cardiopulmonary exercise test (iCPET), and cardiac magnetic resonance imaging (MR), 6-minute walk distance (6MWD), pharmacokinetic parameters, pharmacodynamic parameters, anti-drug antibody testing, and adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented findings on RHC at any time prior to Screening consistent with a diagnosis of World Health Organization (WHO) pulmonary hypertension Group 1: PAH of any of the following subtypes:
Pulmonary function tests within 6 months prior to Screening as follows:
Exclusion Criteria:
Participants will be excluded from the study if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will receive SOC plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. (Each cycle will be 21 days.) From Cycle 2 through Cycle 9, the dose will be escalated to 0.7 mg/kg SC. Dosing will be every three weeks during the 24-week treatment period and 18-month extension period.
Biological: Sotatercept · Other: SOC
Sotatercept injection
Also known as: ACE-011
SOC therapy refers to combination therapy consisting of drugs from two or more of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks
Each participant's VO2 max was measured by an invasive cardiopulmonary exercise test (iCPET) at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Right Ventricular Stroke Volume (RV SV) at 24 Weeks
Each participant's RV SV was measured by cardiac MRI at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Right Ventricular End-Systolic Volume (RV ESV) at 24 Weeks
Each participant's RV ESV was measured by cardiac MR imaging at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Right Ventricular End-Diastolic Volume (RV EDV) at 24 Weeks
Each participant's RV EDV was measured by cardiac MR imaging at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Percent Change From Baseline in Right Ventricular Ejection Fraction (RV EF) at 24 Weeks
Each participant's RV EF was measured by cardiac MR imaging at baseline and at 24 weeks.
Time frame: Baseline and 24 Weeks
Change From Baseline in Right Ventricular Stroke Volume Index (RV SVI) at 24 Weeks
Each participant's RV SVI was measured by cardiac MR imaging at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Right Ventricular (RV) Mass at 24 Weeks
Each participant's RV mass was measured by cardiac MR imaging at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Ventilatory Efficiency (VE/VCO2 Slope) at 24 Weeks
VE/VCO2 slope refers to the slope of the regression line of Minute Ventilation (VE) in liters/minute in the Y-axis and corresponding carbon dioxide production per minute (VCO2) in liters/minute in the X-axis plotted with multiple measurements taken during exercise. Each participant's VE/VCO2 slope at peak exercise was measured by an iCPET at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Cardiac Index at 24 Weeks
Each participant's cardiac index at peak exercise was measured by iCPET at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Mean Pulmonary Arterial Pressure at 24 Weeks
Each participant's pulmonary arterial pressure at peak exercise was measured by iCPET at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Arteriovenous O2 Content Difference (Ca-vO2) at 24 Weeks
Each participant's Ca-vO2 at peak exercise was measured by iCPET at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks
Each participant's PVR, at resting supine, was measured by right heart catheterization (RHC) at baseline and at 24 weeks.
Time frame: Baseline and 24 weeks
Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks
6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
Time frame: Baseline and 24 weeks
Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks
Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.
Time frame: Baseline and 24 Weeks
Change From Baseline in WHO (World Health Organization) Functional Class at 24 Weeks
The World Health Organization (WHO) functional class describes how severe a person's pulmonary hypertension symptoms are. There are four different classes - I is the mildest and IV the most severe form of pulmonary hypertension.
Time frame: Baseline and 24 Weeks
Number of Participants With One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 24 weeks
Number of Participants Who Experienced One or More Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH)
Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).
Time frame: Up to 102 weeks
Observed Trough Concentration (Ctrough) of Sotatercept at Cycle 9
Ctrough is the plasma concentration of a drug prior to administration.
Time frame: Day 1 of Cycle 9 (Each cycle was 21 days.)
Maximum Plasma Concentration (Cmax) of Sotatercept at Cycle 9
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmax parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
Minimum Plasma Concentration (Cmin) of Sotatercept at Cycle 9
Cmin is a measure of the minimum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmin parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
Average Concentration (Cavg) of Sotatercept at Cycle 9
Cavg is calculated by area under the plasma concentration versus dosing interval time curve at steady-state divided by the dosing interval. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cavg parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
Area Under the Concentration-Time Curve From 0 to T (AUC0-T) of Sotatercept at Cycle 9
AUC0-T (area under the plasma concentration versus time curve from time zero after a dose is given to a period of one 21-day cycle) is a measure of the mean concentration levels of a drug in the plasma at steady state. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The AUC0-T parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
Apparent Terminal Half-life (t1/2 ) of Sotatercept at Cycle 9
t1/2 is the elimination half-life of study drug: the time it takes for half of the study drug in the blood plasma to dissipate. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The t1/2 parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
Apparent Serum Clearance (CL) of Sotatercept at Cycle 9
Apparent serum CL is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The apparent serum CL parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
Apparent Volume of Distribution (Vz/F) of Sotatercept at Cycle 9
Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Vz/F parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
Absorption Rate Constant (Ka) of Sotatercept at Cycle 9
Ka is the proportionality constant that relates the rate of drug absorbed into the body. Ka is a value used to describe the rate at which a drug enters into the system. It is expressed in units of time. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Ka parameter is derived from this preliminary popPK modeling.
Time frame: Day 1 of each 21-day cycle: Cycles 1-9
| Milestone | Sotatercept |
|---|---|
| Started | 21 |
| Completed | 20 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Sotatercept |
|---|---|
| Started | 20 |
| Completed | 19 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Each participant's VO2 max was measured by an invasive cardiopulmonary exercise test (iCPET) at baseline and at 24 weeks.
| mL/min/kg | Sotatercept |
|---|---|
| Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks | 1.28 ± 2.628 |
Each participant's RV SV was measured by cardiac MRI at baseline and at 24 weeks.
| mL | Sotatercept |
|---|---|
| Change From Baseline in Right Ventricular Stroke Volume (RV SV) at 24 Weeks | -27.306 ± 26.5786 |
Each participant's RV ESV was measured by cardiac MR imaging at baseline and at 24 weeks.
| mL | Sotatercept |
|---|---|
| Change From Baseline in Right Ventricular End-Systolic Volume (RV ESV) at 24 Weeks | -39.151 ± 22.5544 |
Each participant's RV EDV was measured by cardiac MR imaging at baseline and at 24 weeks.
| mL | Sotatercept |
|---|---|
| Change From Baseline in Right Ventricular End-Diastolic Volume (RV EDV) at 24 Weeks | -66.459 ± 37.3311 |
Each participant's RV EF was measured by cardiac MR imaging at baseline and at 24 weeks.
| Percent change | Sotatercept |
|---|---|
| Percent Change From Baseline in Right Ventricular Ejection Fraction (RV EF) at 24 Weeks | -1.3 ± 8.48 |
Each participant's RV SVI was measured by cardiac MR imaging at baseline and at 24 weeks.
| mL/m^2 | Sotatercept |
|---|---|
| Change From Baseline in Right Ventricular Stroke Volume Index (RV SVI) at 24 Weeks | -15.073 ± 14.8219 |
Each participant's RV mass was measured by cardiac MR imaging at baseline and at 24 weeks.
| grams | Sotatercept |
|---|---|
| Change From Baseline in Right Ventricular (RV) Mass at 24 Weeks | -6.240 ± 13.3558 |
VE/VCO2 slope refers to the slope of the regression line of Minute Ventilation (VE) in liters/minute in the Y-axis and corresponding carbon dioxide production per minute (VCO2) in liters/minute in the X-axis plotted with multiple measurements taken during exercise. Each participant's VE/VCO2 slope at peak exercise was measured by an iCPET at baseline and at 24 weeks.
| Unitless | Sotatercept |
|---|---|
| Change From Baseline in Ventilatory Efficiency (VE/VCO2 Slope) at 24 Weeks | -8.87 ± 12.298 |
Each participant's cardiac index at peak exercise was measured by iCPET at baseline and at 24 weeks.
| Liter/min/m^2 | Sotatercept |
|---|---|
| Change From Baseline in Cardiac Index at 24 Weeks | 0.411 ± 1.1944 |
Each participant's pulmonary arterial pressure at peak exercise was measured by iCPET at baseline and at 24 weeks.
| mmHg | Sotatercept |
|---|---|
| Change From Baseline in Mean Pulmonary Arterial Pressure at 24 Weeks | -14.9 ± 13.22 |
Each participant's Ca-vO2 at peak exercise was measured by iCPET at baseline and at 24 weeks.
| mL/100 mL | Sotatercept |
|---|---|
| Change From Baseline in Arteriovenous O2 Content Difference (Ca-vO2) at 24 Weeks | 0.63 ± 2.131 |
Each participant's PVR, at resting supine, was measured by right heart catheterization (RHC) at baseline and at 24 weeks.
| dynes*sec/cm^5 | Sotatercept |
|---|---|
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | -305.728 ± 313.9827 |
6MWD is measured by an exercise test known as 6MWT that assesses aerobic capacity and endurance. It measures the distance covered over a time of 6 minutes and is used as an outcome measure by which to compare changes in performance capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicates improvement in basic mobility.
| meters | Sotatercept |
|---|---|
| Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks | 66.35 ± 85.659 |
Each participant's laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were measured at baseline and at 24 weeks.
| pg/mL | Sotatercept |
|---|---|
| Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks | -623.1 ± 840.56 |
The World Health Organization (WHO) functional class describes how severe a person's pulmonary hypertension symptoms are. There are four different classes - I is the mildest and IV the most severe form of pulmonary hypertension.
| WHO functional class | Sotatercept |
|---|---|
| Change From Baseline in WHO (World Health Organization) Functional Class at 24 Weeks | -0.76 ± 0.903 |
An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | Sotatercept |
|---|---|
| Number of Participants With One or More Adverse Events (AEs) | 20 |
Events that indicate clinical worsening of PAH include death, need for and/or worsening-related listing for lung and/or heart transplant, need to initiate an approved PAH SOC rescue therapy, PAH-specific hospitalization, or functional deterioration (worsened WHO Functional Class AND 15% decrease in 6MWD).
| Participants | Sotatercept |
|---|---|
| Number of Participants Who Experienced One or More Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH) | 1 |
Ctrough is the plasma concentration of a drug prior to administration.
| ng/mL | Sotatercept |
|---|---|
| Observed Trough Concentration (Ctrough) of Sotatercept at Cycle 9 | 5884.79 ± 2933.77 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmax parameter is derived from this preliminary popPK modeling.
| ng/mL | Sotatercept |
|---|---|
| Maximum Plasma Concentration (Cmax) of Sotatercept at Cycle 9 | 9732.785 ± 2852.373 |
Cmin is a measure of the minimum amount of drug in the plasma after the dose is given. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cmin parameter is derived from this preliminary popPK modeling.
| ng/mL | Sotatercept |
|---|---|
| Minimum Plasma Concentration (Cmin) of Sotatercept at Cycle 9 | 6234.303 ± 2466.046 |
Cavg is calculated by area under the plasma concentration versus dosing interval time curve at steady-state divided by the dosing interval. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Cavg parameter is derived from this preliminary popPK modeling.
| ng/mL | Sotatercept |
|---|---|
| Average Concentration (Cavg) of Sotatercept at Cycle 9 | 8221.907 ± 2749.846 |
AUC0-T (area under the plasma concentration versus time curve from time zero after a dose is given to a period of one 21-day cycle) is a measure of the mean concentration levels of a drug in the plasma at steady state. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The AUC0-T parameter is derived from this preliminary popPK modeling.
| ng*day/mL | Sotatercept |
|---|---|
| Area Under the Concentration-Time Curve From 0 to T (AUC0-T) of Sotatercept at Cycle 9 | 172659.953 ± 57746.622 |
t1/2 is the elimination half-life of study drug: the time it takes for half of the study drug in the blood plasma to dissipate. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The t1/2 parameter is derived from this preliminary popPK modeling.
| Days | Sotatercept |
|---|---|
| Apparent Terminal Half-life (t1/2 ) of Sotatercept at Cycle 9 | 21.919 ± 5.861 |
Apparent serum CL is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The apparent serum CL parameter is derived from this preliminary popPK modeling.
| Liters/day | Sotatercept |
|---|---|
| Apparent Serum Clearance (CL) of Sotatercept at Cycle 9 | 0.213 ± 0.077 |
Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Vz/F parameter is derived from this preliminary popPK modeling.
| Liters | Sotatercept |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Sotatercept at Cycle 9 | 3.969 ± 1.078 |
Ka is the proportionality constant that relates the rate of drug absorbed into the body. Ka is a value used to describe the rate at which a drug enters into the system. It is expressed in units of time. PopPK modeling approach was used to build a population PK model that captures the totality of the observed data from Cycles 1 to 9. The Ka parameter is derived from this preliminary popPK modeling.
| 1/day | Sotatercept |
|---|---|
| Absorption Rate Constant (Ka) of Sotatercept at Cycle 9 | 0.280 ± 0.035 |
Collected over Treatment period: Up to 24 weeks; Extension period: Up to 18 months plus 8-week follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotatercept Treatment Period | 0/21 (0%) | 4/21 (19%) | 14/21 (66.7%) |
| Sotatercept Extension Period | 0/20 (0%) | 2/20 (10%) | 18/20 (90%) |
| Event | Sotatercept Treatment Period | Sotatercept Extension Period |
|---|---|---|
| HyponatraemiaMetabolism and nutrition disorders | 0/21 | 1/20 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/21 | 1/20 |
| HaematocheziaGastrointestinal disorders | 1/21 | 0/20 |
| Complication associated with deviceGeneral disorders | 1/21 | 0/20 |
| HypervolaemiaMetabolism and nutrition disorders | 1/21 | 0/20 |
| Device leakageProduct Issues | 1/21 | 0/20 |
| Event | Sotatercept Treatment Period | Sotatercept Extension Period |
|---|---|---|
| PolycythaemiaBlood and lymphatic system disorders | 3/21 | 5/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/21 | 5/20 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/21 | 5/20 |
| NauseaGastrointestinal disorders | 2/21 | 4/20 |
| Chest painGeneral disorders | 0/21 | 4/20 |
| Peripheral swellingGeneral disorders | 0/21 | 3/20 |
| HeadacheNervous system disorders | 3/21 | 3/20 |
| FatigueGeneral disorders | 3/21 | 2/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/21 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/21 | 2/20 |
| Age, Continuous(years) | Sotatercept |
|---|---|
| Mean | 45.3 ± 15.06 |
| Sex: Female, Male(Participants) | Sotatercept |
|---|---|
| Female | 17 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Sotatercept |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Sotatercept |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 0 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Peak Oxygen Uptake (VO2 max) at Baseline(mL/min/kg) | Sotatercept |
|---|---|
| Mean | 11.02 ± 3.204 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Dec 2021, 32 months.
Results were first posted in Feb 2023, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 32 months is close to that.
Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept
Pulmonary Arterial Hypertension →
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA →